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Abstract
Background: Aspiration pneumonia is an important cause of morbidity and mortality in Parkinson’s disease (PD).
Clinical characteristics of PD patients in addition to specific alterations in swallowing mechanisms contribute to
higher swallowing times and impairment in the effective clearance of the airway. These issues may render patients
more prone to dysphagia and aspiration events. We aimed to determine the frequency of aspiration events in a
hospitalized PD cohort, and to report the number of in-hospital swallow evaluations.
Methods: A retrospective single center chart review of 212 PD patients who had 339 hospital encounters was
performed from January 2011 to March 2013. Demographics, clinical characteristics, and reasons for encounters
were documented. The number of in-hospital aspiration events and the number of swallowing evaluations and
also the implementation of aspiration precautions were recorded.
Results: The cohort had a mean age of 74.1 (SD = 10.1) years with mean disease duration of 6 (SD = 6.3) years.
Fifty-two hospital encounters (15.3 %) were related to a pulmonary cause. In-hospital aspiration pneumonia events
were reported in 8 (2.4 %) of the total encounters. Swallow evaluations were performed in 25 % of all cases, and
aspiration precautions were initiated in 32 % of the encounters. The data revealed that 1/8 patient had swallowing
evaluations performed prior to an aspiration event.
Conclusions: In-hospital aspiration pneumonia events were reported in 2.4 % of the hospitalized PD cohort. Preventive
measures and precautions were not routinely performed, however rates of aspiration were relatively low. The results
highlight the need for more research into screening and monitoring of swallowing problems in PD patients during
hospital encounters.
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Background
Parkinson’s disease (PD) is a neurodegenerative disorder
characterized by the presence of cardinal motor symptoms
such as bradykinesia, tremor, rigidity, and loss of postural
reflexes [1]. Over the last few decades, there has been
an expanded concept recognizing numerous non-motor
characteristics of PD beyond the usual motor symptoms,
including neuropsychiatric disorders, sleep disturbances,
autonomic, sensory, and gastrointestinal symptoms [2].
These non-motor symptoms become more prevalent as
the disease advances and have been cited as a major cause
of disability. The recognition of these symptoms will likely
be critical for improving healthcare for the expanding PD
population [3, 4].
Dysphagia in PD has been shown to be associated with
aspiration pneumonia, which is one of the potential reasons
for PD hospitalization [5, 6]. Swallowing is a sensorimotor
process involving automatic and volitional systems, where
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decreased cough sensitivity and elevation and excursion of
the hyolaryngeal complex have been considered important
causes of penetration and aspiration in PD patients [7, 8].
PD patients experience higher rates of hospital-based com-
plications, and often suffer substantial clinical deterioration
while hospitalized [9, 10]. It has been estimated that
PD patients have a 3.8 times increased risk of developing
aspiration pneumonia when compared to the general popu-
lation [11]. Aspiration pneumonia has been reported as the
most frequent cause of death in PD patients, and it has
been estimated to account for 70 % of the mortality [12].
The recognition of potentially preventable risk factors and
interventions to reduce morbidity, mortality, and economic
burdens are important and relevant to this population.
We aimed to evaluate the frequency of aspiration events
in patients with PD during hospital encounters, and we
documented the care practices for these patients.
Methods
The University of Florida (UF) Institutional Review Board
(IRB) reviewed and approved the study. Patient records
were de-identified prior to analysis.
Study design, settings, and population
A dataset of 339 hospital encounters from 212 patients
followed at the UF Center for Movement Disorders and
Neurorestoration (CMDNR) was used. The dataset in-
cluded the period from January 2011 to March 2013
and the study was conducted as a retrospective cross-
sectional data/chart review. A diagnosis code (International
Classification of Diseases, Ninth Revision, Clinical Modifica-
tion) was used to identify subjects with PD (ICD-9-CM
code 332.0) who had a hospital encounter and this was
used as criteria for inclusion into the study. A hospital
encounter was defined as an emergency room visit with
subsequent hospitalization, or any direct admission to
the hospital due to any cause with the exception of ad-
mission for elective procedures.
Data collection
An electronic health record system (EPIC) was used to
obtain the basic demographics and clinical data elements
from each subject’s chart at the time of the hospital en-
counter, including results from swallow evaluations and
if aspiration precautions were administered. Additionally,
the reason for hospital encounter, length of hospital stay in
days, and whether a neurologist was consulted during these
encounters were also documented. LED was calculated
using the following formula [13]: regular LD dose + LD
CR dose × 0.75 + LD × 0.33 if entacapone + pramipexole
dose × 100 + ropinirole dose × 20 + rotigotine dose × 30 +
pergolide dose × 1 + bromocriptine dose × 10 + selegiline
dose × 10 + rasagiline dose × 100 + amantadine dose × 1.
The Charlson index score, which has previously been used
in studies with PD patients [14] was chosen to evaluate
the magnitude of impact of each of the comorbidities on
the mortality risk [15]. The Charlson index predicts the
ten-year mortality for each patient based on comorbidities.
Each condition is assigned a score of 1, 2, 3, or 6, depend-
ing on the risk of dying associated with each one. Scores
are summed to provide a total score to predict mortality.
Conditions screened by the Charlson index are cardiovas-
cular disorders, pulmonary diseases, cerebrovascular dis-
eases, connective tissue diseases, liver and kidney diseases,
diabetes, dementia, cancer, and/or AIDS. We further di-
vided patients into subgroups including those with or with-
out alteration in mental status according to the physicians
clinical examination note at the time of evaluation. Reasons
for hospital encounters were categorized based on the
Emergency Severity Index (ESI) triage algorithm [16] which
classifieds the documented reasons for hospitalization. Ac-
cording to this algorithm, an ESI 1 and 2 were classified as
a high risk for a prolonged length of stay, including falls/
fractures, pulmonary causes (such as chronic obstructive
pulmonary disease, cancer, pulmonary arterial hypertension,
fibrosis, vascular disease, pneumonia), cardiac issues/
syncope, genitourinary infections, encephalopathy/drug-in-
duced psychosis, cancer, stroke, and dementia, and an ESI
3–5 was classified as low risk, and was inclusive of general
medical conditions (including weakness, pain, bleeding, or
anorexia), other medical issues (including seizures, vascular
problems, or trauma), and gastrointestinal issues.
Outcome measurements
The primary outcome was the frequency of aspiration
pneumonia in a cohort of PD patients during their hos-
pital encounter. Also collected were the circumstances for
the aspiration event, including clinical features of the indi-
vidual and environmental features such as the occurrence
of swallow evaluations and aspiration precautions.
To identify subjects who developed aspiration pneumonia
during the encounter (in-hospital aspiration) we used a
diagnosis code (ICD-9-CM code 507.0, 507.8, and 997.32)
and performed a manual chart review of each subject and
each hospital encounter in order to identify aspiration
pneumonia events that occurred at 48 h or greater after the
hospital encounter. The frequency of aspiration pneumonia
was calculated by dividing the number of hospital-acquired
aspiration pneumonias by the total number of hospital
encounters, and this was then multiplied by 100. A brief
description of the swallowing evaluations and aspiration
precautions is provided in following paragraphs.
Clinical or bedside swallow evaluation (CSE)
The CSE was performed for all patients referred for a
swallow evaluation. The assessment included: 1. Patient
awake/oriented/able to follow simple commands, 2. Ability
to produce sustained phonation and comment on vocal
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quality, 3. Ability to produce voluntary cough on command,
4. Ability to produce saliva, swallow on command, and ob-
servation of hyolaryngeal elevation, 5. Trials of ice-chips:
observation of oral bolus manipulation; chew (if present);
timeliness of pharyngeal swallow; hyolaryngeal elevation;
cough after swallow; voice quality after swallow, and 6.
Trials of thin, nectar-thick, honey-thick liquids as deemed
appropriate by the speech-language pathologist (SLP):
Anterior labial leakage, timeliness of pharyngeal swallow,
hyolaryngeal elevation, cough after swallow, and voice qual-
ity after swallow.
Rehabilitation barium swallow evaluation (RBS)
The decision to perform a RBS was made following a
CSE and if the patient exhibited signs or symptoms of
an impaired swallowing mechanism. These signs included
one or more of the following: weak or absent volitional
cough, cough after swallow, voice change after swallow,
absent volitional swallow, reduced or delayed hyolaryngeal
elevation. The RBS was performed in the fluoroscopy suite
of the radiology department. Patients were seated upright
in the lateral viewing plane, and multiple boluses of thin,
thick, and solid consistencies were presented for evalu-
ation by the SLP.
Aspiration precautions
The recommendation for aspiration precautions was po-
tentially performed before or possibly after the swallow
evaluations (whether CSE or RBS). These were typically
administered pre-emptively to patients considered by
the nurses or physicians to be at-risk for aspiration, but
they could also be administered after a swallowing study.
The recommendations ranged from nothing by mouth
(NPO) in extreme cases of disordered swallowing, or in-
cluded modifications such as supervision during eating/
drinking, sitting upright in a chair, thickened liquids,
crushed pills, IV administered pills/medications, or various
“dysphagia diets” (i.e., mechanical soft, puree, etc.).
Statistical analysis
A Mann–Whitney U Test was used to compare demo-
graphics and continuous variables (age, Charlson index,
disease duration, levodopa equivalent dosage, days from
admission to swallow evaluations and aspiration precau-
tions, and length of hospital encounter) between those
who developed aspiration pneumonia versus those who
did not develop aspiration pneumonia. A Chi square test
using an Exact Test was performed to compare categorical
variables (gender, H&Y stage, and neurology consultation)
between populations and to learn whether preventive
swallowing measures had an effect on developing aspir-
ation pneumonia during the hospital encounter. Statistical
analyses were performed using commercially available
statistical software (SPSS, version 19.0; SPSS, Inc., Chicago,
Illinois) with a priori alpha levels of ≤ 0.05.
Results
Characteristics of population
Sixty-one percent were male, with a mean age of 74.1
(SD = 10.1) years, and a mean Charlson index of 5.9
(SD = 1.5). The cohort had mean disease duration of
6.4 (SD = 6.3) years and had mean LED of 502.4 (SD =
487.9) mg. A neurologist was consulted in 24.5 % and
the mean length of hospital stay was of 6 (SD = 7.1)
days. No demographic and clinical significant differences
were found when comparing those who developed aspir-
ation pneumonia during hospital encounter versus those
who did not develop aspiration pneumonia, as shown in
Table 1. A pulmonary reason was the cause leading to a
hospital encounter in 52/339 (15.3 %). The reasons for
hospital encounters have been described in Table 2.
Aspiration pneumonia, swallow evaluations and
aspiration precautions
Aspiration pneumonia events were reported in 8 (2.4 %)
hospital encounters of 8 individual patients. The reasons
for hospital encounters were: 3 due to general medical
problems, 2 due falls/fractures, 2 due to other pulmon-
ary causes, and 1 due to other reasons. Seven subjects of
the 8 who developed aspiration pneumonia during the
hospital encounter were considered as having a high-risk
reason of admission, X2 (2) = 2.9, p = 0.09. Two of the 8
subjects had altered mental status at admission and there
was no significant difference in the frequency of aspiration
events when compared to those without alteration, X2
(2) = 0.36, p = 0.72. Additionally, 6/52 (11.5 %) hospital
encounters that were related to pulmonary causes were due
to an aspiration pneumonia acquired outside the hospital.
The swallow evaluations were performed in 83/339
(24.5 %) while aspiration precautions were adopted in
116/339 (34.2 %) of the hospital encounters. The mean
days from admission until swallow evaluation was of 4.5
(SD = 4.3) for RBS and 3.5 (SD = 4.7) for CSE. A greater
percentage of swallow evaluations and aspiration precau-
tions was performed on those who developed in-hospital
aspiration pneumonia, 7/8 (87.5 %) vs. 1/8 (12.5 %), X2
(2) = 5.51, p < 0.03. The evaluations and/or precautions
were implemented after the occurrence of aspiration
pneumonia in 7/8 cases. Two of the 8 in-hospital aspir-
ation pneumonia events developed after an intubation
procedure.
Discussion
This retrospective cross-sectional review of 339 hospital
encounters revealed a frequency of in-hospital aspiration
pneumonia of 2.4 %. Studies have reported an estimated
incidence of community-acquired pneumonia in PD
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patients varying between 11–60 % [17, 18], but there
has been a lack of data on hospitalized patients.
This cohort demonstrated a surprisingly low frequency
of in-hospital swallowing evaluations and also there was
a low amount of education offer in hospital for aspiration
precautions. Swallowing evaluations were ordered in less
than 25 % of cases, and there was a mean delay from ad-
mission of 3–5 days. Aspiration precautions were adminis-
tered in less than 35 % of the hospital encounters. Swallow
evaluations were more frequently implemented following
the discovery of hospital-acquired aspiration pneumonia.
A closer inspection of the data revealed that two of the
eight in-hospital aspiration pneumonia events developed
after an intubation procedure.
The original reports of swallowing complications in
PD were published in the 1980s [19], and since that time
there has been a recent interest in aspiration in this
population, and this interest has been magnified by the
published associations of aspiration with morbidity and
mortality. PD patients without symptoms of dysphagia
have prolonged swallowing times [20, 21] and impairments
in the ability to effectively clear the airways [7, 22, 23].
These attributes render these patients more prone to
developing dysphagia and to subsequent aspiration. Recent
studies have also detected microscopic neural degener-
ation, regenerative changes [24], and deposition of alpha-
synuclein in the pharyngeal structures [25], and these
could possibly be the pathophysiological underpinnings
of swallowing abnormalities in PD.
Interestingly, the demographic, clinical characteristics,
or mental status at admission correlated with aspiration
events. However, we did observe a tendency for developing
aspiration pneumonia in high-risk patients with prolonged
length of stay. In the future it will be important to detect
high-risk PD patients for aspiration at the time of the
hospital admission. Awareness among hospital staff and
physicians and the implementation of preventative mea-
sures could be a critical change in practice. Whether
addressing these issues could decrease the incidence of
aspiration remains unknown.
Preventative measures have been proposed as fundamen-
tal for decreasing aspiration-related morbidity and mortality
in PD [26, 27]. Swallowing function usually does not re-
spond to levodopa therapy, however in some cases it may
be partially improved [28], non-pharmacological measures
[29] such as providing adequate nutrition without sacri-
ficing airway safety are also important. There are no stan-
dardized guidelines for the management of the hospitalized
PD patients and better management protocols are needed
[30, 31].
There were several limitations of this study. The retro-
spective nature of the data obtained from ER clinical
notes could have possibly resulted in missing aspiration
cases and inaccurate staging of the disease. Additionally,
the cognitive profile was not well documented for all
patients. Second, we based the diagnosis of aspiration
pneumonia on the physician’s clinical note. The use of
Table 1 Demographic and clinical comparison between populations
Total (n = 339) Aspiration pneumonia (n = 8) Non-aspiration pneumonia (n = 331) P
Age, y (SD) 74.1 (10.1) 76.6 (12.4) 74.1 (10.1) 0.62a
Male, no. (%) 206 (60.8 %) 4 (50) 202 (61) 0.72b
Charlson index, no. (SD) 5.9 (1.5) 5.9 (1.1) 5.9 (1.5) 0.90a
Disease duration, y (SD) 6.4 (6.3) 3.8 (2.2) 6.4 (6.3) 0.59a
Hoehn and Yahr stage IV-V, no. (%) 165 (48.7) 4 (50) 161 (48.6) 1.00b
LED, no. (SD) 502.4 (487.9) 716.6 (488.5) 496.8 (487.5) 0.15a
Neurologist consulted, no. (%) 83 (24.5) 1 (12.5) 82 (24.8) 0.71b
Length of hospital stay, days (SD) 6 (7.1) 4.3 (3.6) 6.0 (7.2) 0.56a
Swallow evaluations or aspiration precautions, no. (%) 158 (46.6) 7 (87.5) 1 (12.5) 0.03b
Days from admission to barium evaluation, no. (SD) 4.5 (4.3) 4.3 (4.3) 4.5 (4.4) 0.98a
Days from admission to clinical evaluation, no. (SD) 3.5 (4.7) 4.3 (2.2) 3.5 (4.8) 0.13a
aMann–Whitney U Test
bFisher’s Exact Test




General medical problems 51 15
Other 48 14.2
Gastrointestinal issues 43 12.7
Encephalopathy/drug-induced psychosis 24 7.1
Cardiac issues/syncope 22 6.5
Stroke 19 5.6
Genitourinary infections 13 3.8
Cancer 6 1.8
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microbiological cultures from pulmonary aspirates could
have possibly improved diagnostic certainty. Third, the data
was culled from a referral center of movement disorders
and all patients were followed in an expert PD clinic, which
routinely performs swallow evaluations, and this may have
biased the low rate of aspiration events. Finally, the use of
non-validated stratifying indexes (in PD populations) may
have limited the validity of the data. The assessment of
length of hospital stay was based on the Charlson index,
which consider various comorbidities. We were not able to
control for these comorbidities including dementia [32]
and to control for stroke or diabetes [33]. These comorbidi-
ties can impact risk of aspiration. The comorbidity issue
could not be completely addressed due to a lack of statis-
tical power for such an analysis. Finally, the population had
a mean disease duration of 6 years, which could have
possibly underestimated the incidence, and magnitude
of the results.
Conclusions
In summary, though in-hospital aspiration pneumonia
events were reported to be low in our PD cohort this
should not diminish the importance of these events.
Swallowing evaluations and precautions were routinely
underutilized. Additional larger prospective studies from a
community hospital sample will be necessary to better
understand risk factors, preventative strategies, and also
longitudinal follow-up of in-hospital aspiration events.
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